Skip to main content
. 2023 Aug 10;16(10):1957–1971. doi: 10.1111/cts.13604

FIGURE 7.

FIGURE 7

TXNDC12 knockdown can enhance tumor inhibitory effects of erastin. (a) Representative images of clonability analysis of U87 and U251 cells transfected with control, TXNDC12 shRNA, or SLC7A11 and treated with DMSO or erastin (10 μM). (b,c) Control, TXNDC12 shRNA, or SLC7A11 U87 cells were transplanted into the craniums of immunodeficient 5‐week‐old nude mice (5 × 105 cells/mouse). Starting on day 7, erastin (15 mg/kg intracranial injection twice every other day) was administered to treat the tumors in situ. Tumor formation was assessed using bioluminescence imaging on day 20. (d) Representative images of H&E staining of intracranial tumor sections from mice. (e) Relative volume of H&E‐stained sections of intracranial tumors in mice. (f) Kaplan–Meier animal survival analysis (n = 6 mice/group). Data shown represent mean ± SD from three independent experiments. Comparisons were made using the Student's t‐test. ***p < 0.001. H&E, hematoxylin and eosin; ns, not significant; ROS, reactive oxygen species.